World Courier Authorized by UK Wholesale Distribution
Designed to ensure patients and patients in clinical trials safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive.
World Courier, a global provider in specialty logistics and an AmerisourceBergen company, has been granted Wholesale Distribution Authorization (WDA) by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). The WDA is a benchmark certifying the company’s quality systems and processes for storing and distributing pharmaceuticals.
Designed to ensure patients and patients in clinical trials safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive. MHRA regulations require WDA for companies that store shipments of pharmaceutical products for longer than 36 hours or have a refrigerated storage facility for pharmaceuticals. The company also met requirements to demonstrate compliance with the European Union’s Good Distribution Practice (GDP), guidelines that regulate the storage and transportation of medicinal products intended for human consumption.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
